Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed invasive adenocarcinoma of the breast~  * Confined to the breast and ipsilateral axilla on clinical exam~    * Stage I, II, or IIIA (cT1-3, N0-1, M0)~* At least one axillary lymph node with evidence of tumor on histologic exam~  * Sentinel node biopsy allowed if followed by axillary dissection~ * No suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless proven on biopsy to not be involved with tumor~* No bilateral malignancy or mass in the opposite breast, unless mass is histologically proven to be benign~* Must have undergone either a prior total mastectomy and axillary dissection (modified radical mastectomy) OR~* Prior lumpectomy and axillary dissection~  * Patients must receive radiotherapy after randomization (not before) AND after chemotherapy~ * Margins must be clear~ * No ipsilateral lymph nodes that are fixed to one another or to other structures (N2 disease) and/or any positive nonaxillary lymph nodes (intramammary nodes are considered axillary nodes)~ * No histologically evident invasive tumor or ductal carcinoma in situ~ * No diffuse tumors by mammography that would not be surgically amenable to lumpectomy~ * No other dominant mass in the ipsilateral breast remnant unless one of the following is true:~    * Histologically benign~   * Surgically removed with clear margins if malignant~* No ulceration, erythema, infiltration of the skin or underlying chest wall (complete fixation), peau d'orange, or skin edema of any magnitude~  * Tethering or dimpling of the skin or nipple inversion allowed~* No metastatic disease~  * Skeletal pain allowed if bone scan negative for metastases~* Hormone receptor status:~  * Estrogen and progesterone status determined~PATIENT CHARACTERISTICS:~Age:~* greater than or equal to 18 years~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* Not specified~Life expectancy:~* At least 10 years, excluding diagnosis of cancer~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3 (may be less, if in the opinion of the investigator, this represents an ethnic or racial variation)~* Platelet count at least 100,000/mm\^3\* NOTE: \*If platelet count is above the upper limit of normal (ULN), significant underlying hematologic disorders must be excluded~Hepatic:~* Bilirubin no greater than ULN~* Alkaline phosphatase less than 2.5 times ULN\*~* SGOT less than 1.5 times ULN\*~* No nonmalignant systemic hepatic disease that would preclude study participation NOTE: \*Alkaline phosphatase and SGOT cannot both be greater than ULN~Renal:~* Creatinine no greater than normal~* No nonmalignant systemic renal disease that would preclude study participation~Cardiovascular:~* No nonmalignant systemic cardiovascular disease that would preclude study participation~* LVEF at least lower limit of normal (LLN) by MUGA or echocardiogram~* No active cardiac disease that would preclude use of doxorubicin or docetaxel, including the following:~  * Any prior myocardial infarction~ * Angina pectoris requiring anti-anginal medication~ * History of congestive heart failure~ * Cardiac arrhythmia requiring medication~ * Severe conduction abnormality~ * Valvular disease with documented cardiac function compromise~ * Cardiomegaly on chest x-ray or ventricular hypertrophy on EKG, unless LVEF at least LLN~ * Poorly controlled hypertension (diastolic greater than 100 mm/Hg)~ * Hypertension well controlled by medication allowed~Other:~* No grade 2 or greater peripheral neuropathy~* No other prior malignancy within the past 5 years except:~  * Effectively treated squamous cell or basal cell skin cancer~ * Surgically treated carcinoma in situ of the cervix~ * Segmentally resected lobular carcinoma in situ of the ipsilateral or contralateral breast~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception~* No nonmalignant systemic disease that would preclude study participation~* No diabetes with morning fasting blood glucose of 200 mg/dL or greater~* No psychiatric or addictive disorders that would preclude informed consent~* No contraindication to corticosteroids that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior immunotherapy for breast cancer~Chemotherapy:~* No prior chemotherapy for breast cancer~* No prior anthracyclines or taxanes~* No other concurrent investigational chemotherapy~Endocrine therapy:~* No prior hormonal therapy for breast cancer~* No concurrent hormonal birth control methods or other hormonal therapy~* No concurrent raloxifene, including for osteoporosis~* Concurrent low-dose topical estrogen in the form of conjugated estrogen ring or conjugated estrogen vaginal cream (dose no more than 0.3 mg or 1/8 of an applicator applied vaginally 3 times a week) allowed~Radiotherapy:~* See Disease Characteristics~* No prior radiotherapy for this malignancy~Surgery:~* See Disease Characteristics~* No more than 84 days since prior surgery for breast cancer (e.g., lumpectomy, mastectomy, sentinel node biopsy, axillary dissection, or re-excision of lumpectomy margins)~Other:~* No prior systemic therapy for this malignancy~* No concurrent medications that alter cardiac conduction (e.g., digitalis, beta blockers, or calcium-channel blockers) for cardiac arrhythmia, angina, or congestive heart failure (allowed if administered for other reasons \[e.g., hypertension\])~* Concurrent bisphosphonates allowed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Doxorubicin + Cyclophosphamide, then Docetaxel (Type: EXPERIMENTAL): Doxorubicin + Cyclophosphamide, then Docetaxel
- Arm 2: Doxorubicin + Docetaxel (Type: EXPERIMENTAL): Doxorubicin + Docetaxel
- Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide (Type: EXPERIMENTAL): Doxorubicin + Docetaxel + Cyclophosphamide

Based on this trial design, predict the completion outcome and termination type (if applicable).